Last reviewed · How we verify

Ginkgo biloba & Methylprednisolone — Competitive Intelligence Brief

Ginkgo biloba & Methylprednisolone (Ginkgo biloba & Methylprednisolone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: herbal antioxidant + corticosteroid. Area: Neurology.

phase 3 Combination therapy: herbal antioxidant + corticosteroid Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Ginkgo biloba & Methylprednisolone (Ginkgo biloba & Methylprednisolone) — Asan Medical Center. This combination uses Ginkgo biloba's antioxidant and neuroprotective properties alongside methylprednisolone's anti-inflammatory and immunosuppressive effects to reduce neuroinflammation and promote recovery.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ginkgo biloba & Methylprednisolone TARGET Ginkgo biloba & Methylprednisolone Asan Medical Center phase 3 Combination therapy: herbal antioxidant + corticosteroid

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: herbal antioxidant + corticosteroid class)

  1. Asan Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ginkgo biloba & Methylprednisolone — Competitive Intelligence Brief. https://druglandscape.com/ci/ginkgo-biloba-methylprednisolone. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: